Walleye Capital’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-165,583
Closed -$6.97M 5023
2025
Q4
$6.97M Buy
165,583
+133,874
+422% +$5.4M 0.02% 900
2025
Q3
$1.09M Buy
+31,709
New +$910K ﹤0.01% 2025
2024
Q1
Sell
-11,544
Closed -$318K 5924
2023
Q4
$318K Sell
11,544
-108,986
-90% -$2.63M ﹤0.01% 3329
2023
Q3
$2.69M Buy
+120,530
New +$3.1M 0.01% 1503
2021
Q3
Sell
-11,815
Closed -$472 1827
2021
Q2
$472 Buy
+11,815
New +$505K 0.02% 769
2019
Q3
Sell
-413
Closed -$12K 2284
2019
Q2
$12K Buy
+413
New +$10.3K ﹤0.01% 1580

Other funds holding VCYT

Walleye Capital's VCYT Position: Q1 2026 in Review

Walleye Capital sold out of Veracyte (VCYT) in Q1 2026, closing a stake of 165,583 shares — an estimated $6.97M sold.

Walleye Capital first reported a position in VCYT in Q2 2019 and held it in 6 quarters. The position peaked at $6.97M in Q4 2025. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Walleye Capital reported no remaining Veracyte position as of Q1 2026 after selling out during the quarter.
  • Walleye Capital sold 165,583 Veracyte shares in Q1 2026, an estimated $6.97M.
  • Walleye Capital first reported a position in Veracyte in Q2 2019 and held it in 6 quarters.
  • Walleye Capital's Veracyte position peaked at $6.97M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.